RESUMEN
Subarachnoid hemorrhage is a neurologic emergency and a detrimental cerebrovascular event with a high rate of death and complications. Recommendations have been developed and based on literature search, evaluation of the results of large international clinical trials, collective experience of the authors, and endorsed by the Croatian Society of Neurovascular Disorders, Croatian Society of Neurology including Section for Neurocritical Care, Croatian Neurosurgical Society, Croatian Society for Difficult Airway Management and Croatian Medical Association. The aim of these guidelines is to provide current and comprehensive recommendations and to assist physicians in making appropriate decisions in the management of subarachnoid hemorrhage. Evidence based information on the epidemiology, risk factors and prognosis, as well as recommendations on diagnostic work up, monitoring and management are provided, with regard to treatment possibilities in Croatia.
Asunto(s)
Hemorragia Subaracnoidea/diagnóstico , Hemorragia Subaracnoidea/terapia , Diagnóstico por Imagen , Procedimientos Endovasculares , Humanos , Procedimientos Neuroquirúrgicos , Hemorragia Subaracnoidea/complicacionesRESUMEN
These are evidence based guidelines for the management of medical complications in patients following aneurysmal subarachnoid hemorrhage, developed and endorsed by the Croatian Society of Neurovascular Disorders, Croatian Society of Neurology including Section for Neurocritical Care, Croatian Neurosurgical Society, Croatian Society for Difficult Airway Management and Croatian Medical Association. They consist of recommendations for best monitoring, medical treatment and interventions based on the literature, evaluation of the results of large international clinical trials, and collective experience of the authors.
Asunto(s)
Hemorragia Subaracnoidea/complicaciones , Hemorragia Subaracnoidea/terapia , Antifibrinolíticos/uso terapéutico , Isquemia Encefálica/diagnóstico , Isquemia Encefálica/etiología , Isquemia Encefálica/prevención & control , Diagnóstico por Imagen , Humanos , Hidrocefalia/diagnóstico , Hidrocefalia/etiología , Hidrocefalia/prevención & control , Prevención Secundaria , Hemorragia Subaracnoidea/diagnóstico , Vasoespasmo Intracraneal/diagnóstico , Vasoespasmo Intracraneal/etiología , Vasoespasmo Intracraneal/prevención & controlRESUMEN
Gastric pentadecapeptide BPC 157 (GEPPPGKPADDAGLV, an anti-ulcer peptide, efficient in inflammatory bowel disease trials (PL 14736), no toxicity reported, improved muscle crush injury. After an induced traumatic brain injury (TBI) in mice by a falling weight, BPC 157 regimens (10.0microg, 10.0ng/kgi.p.) demonstrated a marked attenuation of damage with an improved early outcome and a minimal postponed mortality throughout a 24h post-injury period. Ultimately, the traumatic lesions (subarachnoidal and intraventricular haemorrhage, brain laceration, haemorrhagic laceration) were less intense and consecutive brain edema had considerably improved. Given prophylactically (30 min before TBI) the improved conscious/unconscious/death ratio in TBI-mice was after force impulses of 0.068 Ns, 0.093 Ns, 0.113 Ns, 0.130 Ns, 0.145 Ns, and 0.159 Ns. Counteraction (with a reduction of unconsciousness, lower mortality) with both microg- and ng-regimens included the force impulses of 0.068-0.145 Ns. A higher regimen presented effectiveness also against the maximal force impulse (0.159 Ns). Furthermore, BPC 157 application immediately prior to injury was beneficial in mice subjected to force impulses of 0.093 Ns-TBI. For a more severe force impulse (0.130 Ns, 0.145 Ns, or 0159 Ns), the time-relation to improve the conscious/unconscious/death ratio was: 5 min (0.130 Ns-TBI), 20 min (0.145 Ns-TBI) or 30 min (0.159 Ns-TBI).
Asunto(s)
Antiulcerosos/farmacología , Encéfalo/efectos de los fármacos , Fragmentos de Péptidos/farmacología , Proteínas/farmacología , Animales , Lesiones Encefálicas/tratamiento farmacológico , Masculino , Ratones , Ratones Endogámicos , Factores de TiempoRESUMEN
Department of Neurology, Split University Hospital has 77 contracted hospital beds. 70 health professionals were employed in the Department; 17 medical doctors and 53 nurses. Aim was to evaluate work results in the one-year period with emphasis on the number of employed health professionals compared to the standards defined by the Ministry of Health. Age median of medical doctors specialists was 42.0 years. Length of stay median was 8.0 days. Average bed occupation rate in the Department of Neurology in 2005 was 88%. Shortage of nurses in the Department was determined as the result of analyses of required number of nurses for the Department compared with national standards. Despite the shortage of medical professionals in the Department, work results were better than national, displayed with average bed occupation rate and average length of stay. Neurological diseases have growing share in the human pathology, and adequate organization and implementation of out-of-clinic and clinic health services is a priority in the national health strategy.
Asunto(s)
Departamentos de Hospitales/estadística & datos numéricos , Neurología , CroaciaRESUMEN
INTRODUCTION: Multiple sclerosis (MS) is a neurological impairment mostly affecting younger adults substantially decreasing their working and living abilities. Different rating scales to determine disabilities are being used: EDSS, NRS, and CAMBS. The objective of this study was to assess the quality of life in MS patients, with reference to the disease itself and its treatment, comparing patients with MS and a matching healthy control group. METHODS AND SUBJECTS: Subjects were divided into two groups, a group of patients with MS and a control group of healthy subjects. There were 37 MS patients, 25 women and 12 men. Control group consisted of 51 subjects, 39 women and 12 men. There was no statistically significant sex difference. The mean age of the MS patients was 45.9 +/- 12.4 years, and of control group 42.4 +/- 10.3 years; yielding no statistically significant difference. The severity of impairment in MS patients according to EDSS scale was 3 to 3.5. The quality of life determined by the prediction and criterion variables was studied in both MS patients groups and control group. All variables were graded on a 1 to 5 scale. On statistical data processing chi2 test and t-test were used. RESULTS AND DISCUSSION: Predictors referring to family history, sexual life, social life, satisfaction with education, job, social environment, religious life, housing status, financial status and present family life did not differ between the MS and control group. MS patients were less satisfied with their place in society, their state of health and ways of spending their free time. The decrease of satisfaction correlated with the areas generally known to be directly or indirectly affected by MS. As to the criterion variable of 'satisfaction with former way of life' no significant differences were found, since the disease did not affect previous life achievements. MS patients were less satisfied with their status in society, their state of health and ways of spending their free time. Changes occurred as a consequence of substantial life changes caused by the disease, results of treatments and circumstances in which the patients lives. Results obtained indicated that patients were aware of their disease, lower quality of life that limited their daily activities and future plans. Answers referring to the state of health, social status, and sexual activities did not show any statistically significant difference between the groups of MS patients and healthy controls, although it could have been expected according to the experience and customary expectations in such cases. CONCLUSION: MS patients are mainly satisfied with what they have achieved previously as young people; they become dissatisfied in relation to the possible economic and social prospects, and they are aware of their disabilities and weaknesses, inability for professional development, working and workplace relationships, more difficult money acquisition, etc.
Asunto(s)
Esclerosis Múltiple , Calidad de Vida , Adulto , Femenino , Estado de Salud , Humanos , Masculino , Persona de Mediana Edad , Esclerosis Múltiple/psicología , Satisfacción PersonalRESUMEN
We present the 55-year-old woman who has had kidney transplantation three times. She has been treated with immunosuppressive therapy and lamivudine for hepatitis B and C. Nine years after the last transplantation she showed neurological symptoms that presented in the form of confusion and epileptic seizures of the grand mal type. A brain MRI showed large oval zones of hyperintense MR signal in T2-weighted image and hypointense in T1-weighted image around the frontal horns of the lateral ventricles, bilaterally and in both cerebellar hemispheres. After reduction in immunosuppression and the exclusion of lamivudine from therapy, the patient was stable with normal neurological status during the course of next five years. We start from the assumption that the concomitant use of cyclosporin with mycophenolate mofetil and lamivudine, despite normal concentrations of cyclosporin, might cause the accumulation of toxic metabolites and lead to neurotoxicity that mimics PML in a chronic viral environment.
Asunto(s)
Trasplante de Riñón/efectos adversos , Leucoencefalopatía Multifocal Progresiva/etiología , Síndromes de Neurotoxicidad/etiología , Ciclosporina/efectos adversos , Femenino , Humanos , Lamivudine/efectos adversos , Leucoencefalopatía Multifocal Progresiva/diagnóstico , Persona de Mediana Edad , Ácido Micofenólico/efectos adversos , Ácido Micofenólico/análogos & derivados , Síndromes de Neurotoxicidad/diagnósticoRESUMEN
Huntington's disease (HD) is a chronic neurodegenerative disorder, characterized by the following triad of clinical hallmarks: chorea, cognitive impairment and behavior disorders [8]. In 1993 the gene responsible for HD, whose mutation results in HD, was identified and mapped on the chromosome 4p16.3 [6]. The mutation is a characteristic expansion of a CAG nucleotide triplet. In this paper we present a 36-years-old female patient with HD who was submitted to a complete diagnostic procedure including genetic testing. Her pedigree was reconstructed using available medical documentation and tracing other members of her family.